Tatva Chintan Promoters Declare No Share Encumbrance for FY26
Tatva Chintan Pharma Chem Limited promoters and concert parties declare no share encumbrance for the financial year ending March 31, 2026. This disclosure is made under SEBI Takeover Regulations.
This is a standard regulatory filing that confirms the absence of share encumbrances by promoters. It does not introduce new information that is expected to significantly impact the company's stock price or operations.
The announcement is a routine regulatory disclosure regarding share encumbrances and does not contain any new financial information or significant business updates that would indicate a positive or negative sentiment.
Tatva Chintan Pharma Chem Limited has announced that its promoters and persons acting in concert have not made any encumbrance of shares, directly or indirectly, during the Financial Year ended on 31 March 2026. This declaration is made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The declaration was submitted by Chintan Nitinkumar Shah, a promoter of the company, on behalf of himself and other promoter group entities. The list of other promoter group entities includes Chintan NShah(HUF), DarshanaNitinkumar Shah, ShitalChintan Shah, KiritHarilal Shah, Bharti Kirit Shah, ShimoniChintan Shah, Anushka Chintan Shah, Nehal Brijesh Shah, SwetaAshitParikh, Manisha AbhijitZaveri, Kirit H. Shah HUF, Premier Solution Private Limited, Marvel Indenting Private Limited, Unigroup Resources LLP, Universal Distributors, and Universal House.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.